Colorectal Cancer Screening in Average Risk Populations: Evidence Summary
Table 7
Responses of the expert panel to the working group’s conclusions.
Reviewer ratings ()
Conclusions
Strongly disagree (%)
Disagree (%)
Neither agree nor disagree (%)
Agree (%)
Strongly agree (%)
() Strong evidence to support use of fecal tests for occult blood to screen people at average risk for CRC
0
0
1 (4)
10 (37)
16 (59)
() Strong evidence to support the use of FS to screen people at average risk for CRC
0
0
0
7 (26)
20 (74)
() No direct evidence to support the use of colonoscopy to screen people at average risk for CRC, but evidence from FS informs the assessment of benefits and harms of colonoscopy to screen people at average risk for CRC
0
2 (8)
2 (8)
14 (54)
8 (31)
() Insufficient evidence to determine how fecal tests for occult blood perform compared with lower bowel endoscopy to screen people at average risk for CRC
0
2 (8)
4 (15)
13 (50)
7 (27)
() Insufficient evidence to determine how CT colonography performs compared with colonoscopy to screen people at average risk for CRC
0
0
1 (4)
8 (33)
15 (63)
() Insufficient evidence to determine how capsule endoscopy performs compared with colonoscopy to screen people at average risk for CRC
0
0
0
1 (4)
23 (96)
() No evidence to support the use of double-contrast barium enema to screen people at average risk for CRC
0
0
2 (8)
0
23 (92)
() Insufficient evidence to determine how fecal DNA performs compared with guaiac fecal occult blood test (gFOBT) or fecal immunochemical test (FIT) to screen people at average risk for CRC
0
0
0
8 (33)
16 (67)
() Insufficient evidence to support the use of mSEPT9 to screen people at average risk for CRC
0
0
0
2 (8)
23 (92)
() Insufficient evidence to support the use of fecal M2-PK to screen people at average risk for CRC
0
0
0
3 (12)
23 (89)
() Insufficient evidence to support the use of other metabolomic tests to screen people at average risk for CRC
0
0
1 (4)
2 (9)
20 (87)
() Insufficient evidence to support changing ages of initiation and cessation for CRC screening with gFOBT in Ontario
0
1 (4)
1 (4)
9 (36)
14 (56)
() Insufficient evidence to recommend an age of initiation or cessation to screen with FS in people at average risk for CRC
0
0
3 (12)
9 (36)
13 (52)
() Insufficient evidence to recommend an age of initiation or cessation to screen with colonoscopy in people at average risk for CRC
0
0
4 (16)
10 (40)
11 (44)
() Evidence suggests annual or biennial screening using gFOBT in people at average risk for CRC reduces CRC mortality
0
0
1 (4)
11 (42)
14 (54)
() Insufficient evidence to recommend an interval to screen people at average risk for CRC using FIT
